Clinical trial
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have…
NCT00492466 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00492466 |
|---|---|
| Title | Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies |
| Official title | A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies |
| Acronym | RECOVER |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon-beta-1a, methylprednisolone |
| Enrollment | 14 |
| Start date | Mar 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jun 27, 2007 |
| Last update posted | Jan 30, 2008 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: